Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (Quant-Seq 2)
RNA-seq (gene expression) · human · 65 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 65 samples: 16 conditions, mostly with about 4 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Co-targeting SOS1 enhances the antitumor effects of KRAS(G12C) inhibitors by addressing intrinsic and acquired resistanceNature cancer · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE250032_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1051636 and SRA study SRP477629. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 65 samples.
How we read this: 16 replicated groups read from 65 sample titles; they account for 65 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7971630 NCI-H2122 cells, Vehicle_A1 NCI-H2122 cells, Vehicl…
- GSM7971631 NCI-H2122 cells, Vehicle_A2 NCI-H2122 cells, Vehicl…
- GSM7971632 NCI-H2122 cells, Vehicle_A3 NCI-H2122 cells, Vehicl…
- GSM7971633 NCI-H2122 cells, Vehicle_A4 NCI-H2122 cells, Vehicl…
- GSM7971634 NCI-H2122 cells, Vehicle_A5 NCI-H2122 cells, Vehicl…
- GSM7971635 NCI-H2122 cells, BI3406_50mpk_4h_C10 NCI-H2122 cells, BI3406…
- GSM7971636 NCI-H2122 cells, BI3406_50mpk_4h_C11 NCI-H2122 cells, BI3406…
- GSM7971637 NCI-H2122 cells, BI3406_50mpk_4h_C12 NCI-H2122 cells, BI3406…
- GSM7971638 NCI-H2122 cells, BI3406_50mpk_4h_C13 NCI-H2122 cells, BI3406…
- GSM7971639 NCI-H2122 cells, BI3406_50mpk_24h_B6 NCI-H2122 cells, BI3406…
- GSM7971640 NCI-H2122 cells, BI3406_50mpk_24h_B7 NCI-H2122 cells, BI3406…
- GSM7971641 NCI-H2122 cells, BI3406_50mpk_24h_B8 NCI-H2122 cells, BI3406…
- GSM7971642 NCI-H2122 cells, BI3406_50mpk_24h_B9 NCI-H2122 cells, BI3406…
- GSM7971643 NCI-H2122 cells, BI3406_50mpk_48h_D14 NCI-H2122 cells, BI3406…
- GSM7971644 NCI-H2122 cells, BI3406_50mpk_48h_D15 NCI-H2122 cells, BI3406…
- GSM7971645 NCI-H2122 cells, BI3406_50mpk_48h_D16 NCI-H2122 cells, BI3406…
- GSM7971646 NCI-H2122 cells, BI3406_50mpk_48h_D17 NCI-H2122 cells, BI3406…
- GSM7971647 NCI-H2122 cells, Adagrasib_100mpk_4h_F22 NCI-H2122 cells, Adagra…
- GSM7971648 NCI-H2122 cells, Adagrasib_100mpk_4h_F23 NCI-H2122 cells, Adagra…
- GSM7971649 NCI-H2122 cells, Adagrasib_100mpk_4h_F24 NCI-H2122 cells, Adagra…
- GSM7971650 NCI-H2122 cells, Adagrasib_100mpk_4h_F25 NCI-H2122 cells, Adagra…
- GSM7971651 NCI-H2122 cells, Adagrasib_100mpk_24h_E18 NCI-H2122 cells, Adagra…
- GSM7971652 NCI-H2122 cells, Adagrasib_100mpk_24h_E19 NCI-H2122 cells, Adagra…
- GSM7971653 NCI-H2122 cells, Adagrasib_100mpk_24h_E20 NCI-H2122 cells, Adagra…
- GSM7971654 NCI-H2122 cells, Adagrasib_100mpk_24h_E21 NCI-H2122 cells, Adagra…
- GSM7971655 NCI-H2122 cells, Adagrasib_100mpk_48h_G26 NCI-H2122 cells, Adagra…
- GSM7971656 NCI-H2122 cells, Adagrasib_100mpk_48h_G27 NCI-H2122 cells, Adagra…
- GSM7971657 NCI-H2122 cells, Adagrasib_100mpk_48h_G28 NCI-H2122 cells, Adagra…
- GSM7971658 NCI-H2122 cells, Adagrasib_100mpk_48h_G29 NCI-H2122 cells, Adagra…
- GSM7971659 NCI-H2122 cells, TNO155_10mpk_4h_I34 NCI-H2122 cells, TNO155…
- GSM7971660 NCI-H2122 cells, TNO155_10mpk_4h_I35 NCI-H2122 cells, TNO155…
- GSM7971661 NCI-H2122 cells, TNO155_10mpk_4h_I36 NCI-H2122 cells, TNO155…
- GSM7971662 NCI-H2122 cells, TNO155_10mpk_4h_I37 NCI-H2122 cells, TNO155…
- GSM7971663 NCI-H2122 cells, TNO155_10mpk_24h_H30 NCI-H2122 cells, TNO155…
- GSM7971664 NCI-H2122 cells, TNO155_10mpk_24h_H31 NCI-H2122 cells, TNO155…
- GSM7971665 NCI-H2122 cells, TNO155_10mpk_24h_H32 NCI-H2122 cells, TNO155…
- GSM7971666 NCI-H2122 cells, TNO155_10mpk_24h_H33 NCI-H2122 cells, TNO155…
- GSM7971667 NCI-H2122 cells, TNO155_10mpk_48h_J38 NCI-H2122 cells, TNO155…
- GSM7971668 NCI-H2122 cells, TNO155_10mpk_48h_J39 NCI-H2122 cells, TNO155…
- GSM7971669 NCI-H2122 cells, TNO155_10mpk_48h_J40 NCI-H2122 cells, TNO155…
+ 25 more — browse all 65 samples with per-sample file links →
- GSE225060 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (RNA-Seq). 33 samples shares sos1-kras, krasg12c, combination, interaction, resistance, inhibitor, intrinsic
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares combination, resistance, inhibitor
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares combination, inhibitor
- GSE339038 RNA-Seq of CD3+ T cells flow sorted from MLR assays with TNF/TNFR inhibitory compound combination treatments 64 samples shares combination, inhibitor
- GSE289619 IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non–small cell lung cancer II 32 samples shares interaction, resistance
- GSE273769 The PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. 24 samples shares combination, inhibitor
- GSE301688 Preclinical Evaluation of the Efficacy of a Cyclin-dependent Kinase Inhibitor Ribociclib in Combination with Letrozole Against Patient-Derived Glioblastoma Cells 18 samples shares combination, inhibitor
- GSE277035 Pre-clinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms (MPN) transformed to AML 10 samples shares combination, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.